Stallergenes Greer


Stallergenes Greer International AG is a Swiss biopharmaceutical company specializing in the diagnosis and treatment of allergies through allergen immunotherapy.
Headquartered in Baar, Switzerland, Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. and Stallergenes S.A.S..
With 1194 employees in 2024, Stallergenes Greer has a global presence 45 countries through its subsidiaries, manufacturing sites and distribution network.
Stallergenes Greer's core manufacturing facilities are located both in Europe, the United States, and Canada.

History

Stallergenes was founded in 1962 by Institut Mérieux In 2015, Stallergenes and Greer Laboratories Inc. merged to form Stallergenes Greer.
Greer was founded by R.T. Greer, a collector of source materials in 1904.
Stallergenes Greer is a privately held company owned by B-Flexion, chaired by Ernesto Bertarelli.

Activity

Stallergenes Greer specialises in allergy immunotherapy treatments. It includes name patient products which are allergen products, prepared in accordance with prescriptions for individual patients.
The product portfolio covers different segments including sublingual products, subcutaneous products, oral immunotherapy, allergen extracts available as a bulk extract or name patient products, veterinary products, testing supplies, source materials and other supplies like sterile diluents, sterile empty vials.

Governance

The board of directors includes:

Pharmaceutical and clinical development programme

Since 2003, Stallergenes has been involved in a clinical development programme whose objective is to develop proprietary medicines intended to cover the main allergens responsible for more than 80% of respiratory allergies.
Oralair is the first sublingual immunotherapy tablet resulting from this programme. Oralair is marketed in 22 countries and has been approved by the Food and Drug Administration in the United States.
The second project in this programme is the house dust mite immunotherapy tablet Actair which is marketed in Japan, Australia, and New Zealand, and South Korea under the brand name Actair and in Europe under the brand names Orylmyte or Aitmyte.
In 2021, Stallergenes Greer is partnering with Aptar Pharma to develop a novel connected device for allergen immunotherapy treatment delivery. It will contribute to improving adherence, thus optimising treatment outcomes.
In 2023, the group added Palforzia, an oral immunotherapy for peanut allergy, to its portfolio, thereby expanding into the field of food allergy.